ID
29646
Beschrijving
Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Treatment Timetable. Time: Treatment Period 2.
Link
https://clinicaltrials.gov/ct2/show/NCT00318630
Trefwoorden
Versies (1)
- 10-04-18 10-04-18 - Sarah Riepenhausen
Houder van rechten
GlaxoSmithKline
Geüploaded op
10 april 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630
Treatment Timetable - Treatment Period 2
- StudyEvent: ODM
Similar models
Treatment Timetable - Treatment Period 2
- StudyEvent: ODM
C1301732 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0087111 (UMLS CUI-2)
C0087111 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])